ChemoCentryx Competitors

Amgen (NASDAQ:AMGN) and ChemoCentryx (NASDAQ:CCXI) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, risk, valuation and institutional ownership.

Earnings and Valuation

This table compares Amgen and ChemoCentryx's gross revenue, earnings per share (EPS) and valuation.

Amgen has higher revenue and earnings than ChemoCentryx. ChemoCentryx is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

75.2% of Amgen shares are held by institutional investors. Comparatively, 76.4% of ChemoCentryx shares are held by institutional investors. 0.4% of Amgen shares are held by company insiders. Comparatively, 9.3% of ChemoCentryx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Amgen and ChemoCentryx's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent recommendations for Amgen and ChemoCentryx, as provided by MarketBeat.

Amgen presently has a consensus price target of $255.68, suggesting a potential upside of 11.67%. ChemoCentryx has a consensus price target of $72.4444, suggesting a potential upside of 39.21%. Given ChemoCentryx's stronger consensus rating and higher possible upside, analysts plainly believe ChemoCentryx is more favorable than Amgen.

Volatility & Risk

Amgen has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500. Comparatively, ChemoCentryx has a beta of 1.7, meaning that its share price is 70% more volatile than the S&P 500.

Summary

Amgen beats ChemoCentryx on 8 of the 15 factors compared between the two stocks.

Celgene (NASDAQ:CELG) and ChemoCentryx (NASDAQ:CCXI) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Analyst Ratings

This is a summary of current recommendations and price targets for Celgene and ChemoCentryx, as provided by MarketBeat.com.

Celgene presently has a consensus price target of $108.6667, suggesting a potential upside of 0.39%. ChemoCentryx has a consensus price target of $72.4444, suggesting a potential upside of 39.21%. Given ChemoCentryx's stronger consensus rating and higher probable upside, analysts clearly believe ChemoCentryx is more favorable than Celgene.

Earnings & Valuation

This table compares Celgene and ChemoCentryx's top-line revenue, earnings per share and valuation.

Celgene has higher revenue and earnings than ChemoCentryx. ChemoCentryx is trading at a lower price-to-earnings ratio than Celgene, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Celgene and ChemoCentryx's net margins, return on equity and return on assets.

Insider & Institutional Ownership

71.7% of Celgene shares are owned by institutional investors. Comparatively, 76.4% of ChemoCentryx shares are owned by institutional investors. 0.4% of Celgene shares are owned by company insiders. Comparatively, 9.3% of ChemoCentryx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Risk & Volatility

Celgene has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500. Comparatively, ChemoCentryx has a beta of 1.7, meaning that its share price is 70% more volatile than the S&P 500.

Summary

ChemoCentryx beats Celgene on 8 of the 15 factors compared between the two stocks.

ChemoCentryx (NASDAQ:CCXI) and Gilead Sciences (NASDAQ:GILD) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and valuation.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for ChemoCentryx and Gilead Sciences, as provided by MarketBeat.

ChemoCentryx presently has a consensus price target of $72.4444, suggesting a potential upside of 39.21%. Gilead Sciences has a consensus price target of $78.9259, suggesting a potential upside of 31.08%. Given ChemoCentryx's stronger consensus rating and higher possible upside, equities research analysts plainly believe ChemoCentryx is more favorable than Gilead Sciences.

Profitability

This table compares ChemoCentryx and Gilead Sciences' net margins, return on equity and return on assets.

Risk and Volatility

ChemoCentryx has a beta of 1.7, suggesting that its share price is 70% more volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500.

Valuation & Earnings

This table compares ChemoCentryx and Gilead Sciences' revenue, earnings per share (EPS) and valuation.

Gilead Sciences has higher revenue and earnings than ChemoCentryx. ChemoCentryx is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

76.4% of ChemoCentryx shares are owned by institutional investors. Comparatively, 77.9% of Gilead Sciences shares are owned by institutional investors. 9.3% of ChemoCentryx shares are owned by company insiders. Comparatively, 0.1% of Gilead Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Gilead Sciences beats ChemoCentryx on 8 of the 15 factors compared between the two stocks.

ChemoCentryx (NASDAQ:CCXI) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation.

Risk & Volatility

ChemoCentryx has a beta of 1.7, suggesting that its share price is 70% more volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500.

Insider & Institutional Ownership

76.4% of ChemoCentryx shares are held by institutional investors. Comparatively, 85.9% of Regeneron Pharmaceuticals shares are held by institutional investors. 9.3% of ChemoCentryx shares are held by insiders. Comparatively, 11.3% of Regeneron Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares ChemoCentryx and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares ChemoCentryx and Regeneron Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Regeneron Pharmaceuticals has higher revenue and earnings than ChemoCentryx. ChemoCentryx is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and recommmendations for ChemoCentryx and Regeneron Pharmaceuticals, as provided by MarketBeat.

ChemoCentryx presently has a consensus price target of $72.4444, indicating a potential upside of 39.21%. Regeneron Pharmaceuticals has a consensus price target of $622.1250, indicating a potential upside of 8.69%. Given ChemoCentryx's stronger consensus rating and higher possible upside, analysts clearly believe ChemoCentryx is more favorable than Regeneron Pharmaceuticals.

Summary

Regeneron Pharmaceuticals beats ChemoCentryx on 10 of the 14 factors compared between the two stocks.

Vertex Pharmaceuticals (NASDAQ:VRTX) and ChemoCentryx (NASDAQ:CCXI) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, dividends, earnings and valuation.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Vertex Pharmaceuticals and ChemoCentryx, as provided by MarketBeat.com.

Vertex Pharmaceuticals presently has a consensus price target of $294.00, indicating a potential upside of 39.09%. ChemoCentryx has a consensus price target of $72.4444, indicating a potential upside of 39.21%. Given ChemoCentryx's stronger consensus rating and higher possible upside, analysts clearly believe ChemoCentryx is more favorable than Vertex Pharmaceuticals.

Earnings & Valuation

This table compares Vertex Pharmaceuticals and ChemoCentryx's gross revenue, earnings per share (EPS) and valuation.

Vertex Pharmaceuticals has higher revenue and earnings than ChemoCentryx. ChemoCentryx is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

92.2% of Vertex Pharmaceuticals shares are owned by institutional investors. Comparatively, 76.4% of ChemoCentryx shares are owned by institutional investors. 0.5% of Vertex Pharmaceuticals shares are owned by company insiders. Comparatively, 9.3% of ChemoCentryx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Vertex Pharmaceuticals and ChemoCentryx's net margins, return on equity and return on assets.

Volatility & Risk

Vertex Pharmaceuticals has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500. Comparatively, ChemoCentryx has a beta of 1.7, indicating that its stock price is 70% more volatile than the S&P 500.

Summary

Vertex Pharmaceuticals beats ChemoCentryx on 9 of the 14 factors compared between the two stocks.

ChemoCentryx (NASDAQ:CCXI) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

Earnings and Valuation

This table compares ChemoCentryx and Biogen's gross revenue, earnings per share (EPS) and valuation.

Biogen has higher revenue and earnings than ChemoCentryx. ChemoCentryx is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares ChemoCentryx and Biogen's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings and recommmendations for ChemoCentryx and Biogen, as reported by MarketBeat.

ChemoCentryx currently has a consensus target price of $72.4444, suggesting a potential upside of 39.21%. Biogen has a consensus target price of $311.8214, suggesting a potential upside of 15.96%. Given ChemoCentryx's stronger consensus rating and higher probable upside, equities research analysts clearly believe ChemoCentryx is more favorable than Biogen.

Insider and Institutional Ownership

76.4% of ChemoCentryx shares are held by institutional investors. Comparatively, 83.7% of Biogen shares are held by institutional investors. 9.3% of ChemoCentryx shares are held by company insiders. Comparatively, 0.5% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility and Risk

ChemoCentryx has a beta of 1.7, suggesting that its stock price is 70% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.54, suggesting that its stock price is 46% less volatile than the S&P 500.

Summary

Biogen beats ChemoCentryx on 9 of the 15 factors compared between the two stocks.